-
Company Insights
New![]()
Innovation and Patenting activity of ASM International NV Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ASM International NV Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)Drug Details:Bezuclastinib (CGT-9486) is under development for gastrointestinal stromal tumor, advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bezuclastinib in Systemic MastocytosisDrug Details:Bezuclastinib (CGT-9486) is under development for gastrointestinal stromal tumor, advanced systemic mastocytosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MGD-024 in Relapsed Acute Myeloid Leukemia Drug Details:MGD-024 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Systemic Mastocytosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MGD-024 in Systemic Mastocytosis Drug Details:MGD-024 is under development for the treatment of solid tumor and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Secondary Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MGD-024 in Secondary Acute Myeloid LeukemiaDrug Details:MGD-024 is under development for the treatment of solid tumor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGD-024 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drug Details: MGD-024 is under...
-
Product Insights
New![]()
TERMOUTILIZZATORE Biomass Power Plant
TERMOUTILIZZATORE Biomass Power Plant is a biopower project located in Lombardy, Italy. The project is owned by ASM Brescia S.p.A.. The project came online in 1998. Empower your strategies with our TERMOUTILIZZATORE Biomass Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Avapritinib in Breast Cancer Drug Details:Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Solid Tumor Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic agent. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.